This was followed by PD-1 monoclonal antibodies such as nivolumab and pembrolizumab (Nilum, Pyroram) and PD-L1 monoclonal antibodies, which have shown better efficacy and more controlled adverse reactions in the treatment of patients with advanced melanoma (24, 25). The gene discussed is CD274; the disease is melanoma.